Cargando…
Clinical Toxicities of Histone Deacetylase Inhibitors
The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform speci...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034096/ https://www.ncbi.nlm.nih.gov/pubmed/27713375 http://dx.doi.org/10.3390/ph3092751 |
_version_ | 1782317930607804416 |
---|---|
author | Subramanian, Srividya Bates, Susan E. Wright, John J. Espinoza-Delgado, Igor Piekarz, Richard L. |
author_facet | Subramanian, Srividya Bates, Susan E. Wright, John J. Espinoza-Delgado, Igor Piekarz, Richard L. |
author_sort | Subramanian, Srividya |
collection | PubMed |
description | The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform specificities, they surprisingly have very similar toxicity profiles. In contrast, the observed toxicity profile is somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents. While some of the side effects may be familiar to the oncologist, others are less commonly seen. As some patients remain on therapy for a prolonged period of time, the long-term sequelae need to be characterized. In addition, since preclinical models suggest promising activity when used in combination with other antineoplastic agents, combination trials are being pursued. It will thus be important to distinguish the relative toxicity attributed to these agents and be alert to the exacerbation of toxicities observed in single agent studies. Notably, few of the agents in this class have completed phase 2 testing. Consequently, more clinical experience is needed to determine the relative frequency of the observed side effects, and to identify and develop approaches to mitigate potential clinical sequelae. |
format | Online Article Text |
id | pubmed-4034096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-40340962014-05-27 Clinical Toxicities of Histone Deacetylase Inhibitors Subramanian, Srividya Bates, Susan E. Wright, John J. Espinoza-Delgado, Igor Piekarz, Richard L. Pharmaceuticals (Basel) Review The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform specificities, they surprisingly have very similar toxicity profiles. In contrast, the observed toxicity profile is somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents. While some of the side effects may be familiar to the oncologist, others are less commonly seen. As some patients remain on therapy for a prolonged period of time, the long-term sequelae need to be characterized. In addition, since preclinical models suggest promising activity when used in combination with other antineoplastic agents, combination trials are being pursued. It will thus be important to distinguish the relative toxicity attributed to these agents and be alert to the exacerbation of toxicities observed in single agent studies. Notably, few of the agents in this class have completed phase 2 testing. Consequently, more clinical experience is needed to determine the relative frequency of the observed side effects, and to identify and develop approaches to mitigate potential clinical sequelae. MDPI 2010-08-26 /pmc/articles/PMC4034096/ /pubmed/27713375 http://dx.doi.org/10.3390/ph3092751 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Subramanian, Srividya Bates, Susan E. Wright, John J. Espinoza-Delgado, Igor Piekarz, Richard L. Clinical Toxicities of Histone Deacetylase Inhibitors |
title | Clinical Toxicities of Histone Deacetylase Inhibitors |
title_full | Clinical Toxicities of Histone Deacetylase Inhibitors |
title_fullStr | Clinical Toxicities of Histone Deacetylase Inhibitors |
title_full_unstemmed | Clinical Toxicities of Histone Deacetylase Inhibitors |
title_short | Clinical Toxicities of Histone Deacetylase Inhibitors |
title_sort | clinical toxicities of histone deacetylase inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034096/ https://www.ncbi.nlm.nih.gov/pubmed/27713375 http://dx.doi.org/10.3390/ph3092751 |
work_keys_str_mv | AT subramaniansrividya clinicaltoxicitiesofhistonedeacetylaseinhibitors AT batessusane clinicaltoxicitiesofhistonedeacetylaseinhibitors AT wrightjohnj clinicaltoxicitiesofhistonedeacetylaseinhibitors AT espinozadelgadoigor clinicaltoxicitiesofhistonedeacetylaseinhibitors AT piekarzrichardl clinicaltoxicitiesofhistonedeacetylaseinhibitors |